A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors.

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs IW 3718 (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 20 Jul 2017 According to an Ironwood Pharmaceuticals media release, additional data from this study will be presented at an upcoming scientific meeting and/or via peer-reviewed publications.
    • 20 Jul 2017 Top-line results published in an Ironwood Pharmaceuticals Media Release.
    • 20 Jul 2017 Primary endpoint has been met. (Change from baseline in heartburn severity). according to an Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top